NCT06824818 Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
| NCT ID | NCT06824818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Elderly |
| Study Type | INTERVENTIONAL |
| Enrollment | 155 participants |
| Start Date | 2026-06 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 155 participants in total. It began in 2026-06 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Eligibility Criteria
Inclusion Criteria: * Prostate cancer with \>3 years of LHRH agonist therapy. * Age ≥70 years. * ECOG performance status ≤2 * Baseline testosterone of \< 20 ng/ml * No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable). * Ability to understand and sign informed consent. Exclusion Criteria: * none
Contact & Investigator
Nabiel Mir, MD
STUDY CHAIR
University of Chicago
Frequently Asked Questions
Who can join the NCT06824818 clinical trial?
This trial is open to male participants only, aged 70 Years or older, studying Elderly. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06824818 currently recruiting?
Yes, NCT06824818 is actively recruiting participants. Contact the research team at cancerclinicaltrials@bsd.uchicago.edu for enrollment information.
Where is the NCT06824818 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States.
Who is sponsoring the NCT06824818 clinical trial?
NCT06824818 is sponsored by University of Chicago. The principal investigator is Nabiel Mir, MD at University of Chicago. The trial plans to enroll 155 participants.